Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21
Hong Kong (HSI) Drug Retail Industry Analysis
UpdatedApr 25, 2024
DataAggregated Company Financials
Companies5
- 7D6.5%
- 3M-15.7%
- 1Y-56.0%
- YTDn/a
Over the last 7 days, the Drug Retail industry has risen 3.6%, driven by gains from every company within the industry. In the past year, the industry is down 57%. As for the next few years, earnings are expected to grow by 21% per annum.
Industry Valuation and Performance
Has the Hong Kong Drug Retail Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 25 Apr 2024 | HK$141.5b | HK$103.8b | HK$2.3b | 42.2x | 60.8x | 1.4x |
| Sat, 23 Mar 2024 | HK$162.9b | HK$103.5b | HK$13.7m | 49.2x | 11880.2x | 1.6x |
| Mon, 19 Feb 2024 | HK$173.2b | HK$105.1b | -HK$1,456,351,200.68 | 56.6x | -118.9x | 1.6x |
| Wed, 17 Jan 2024 | HK$168.1b | HK$105.1b | -HK$1,456,912,795.00 | 52.2x | -115.4x | 1.6x |
| Fri, 15 Dec 2023 | HK$199.3b | HK$105.8b | -HK$1,465,514,878.00 | 63.9x | -136x | 1.9x |
| Sun, 12 Nov 2023 | HK$212.7b | HK$102.0b | -HK$1,738,786,475.00 | 88.4x | -122.3x | 2.1x |
| Tue, 10 Oct 2023 | HK$221.8b | HK$102.6b | -HK$1,679,792,392.00 | 111.4x | -132x | 2.2x |
| Thu, 07 Sep 2023 | HK$233.4b | HK$102.6b | -HK$1,679,434,210.00 | 81.4x | -139x | 2.3x |
| Sat, 05 Aug 2023 | HK$283.2b | HK$96.2b | -HK$4,171,659,195.00 | 129.4x | -67.9x | 2.9x |
| Mon, 03 Jul 2023 | HK$256.4b | HK$95.5b | -HK$4,143,755,446.00 | 110.6x | -61.9x | 2.7x |
| Wed, 31 May 2023 | HK$271.9b | HK$97.5b | -HK$4,314,153,981.00 | 244x | -63x | 2.8x |
| Fri, 28 Apr 2023 | HK$307.0b | HK$95.3b | -HK$4,880,768,094.00 | 471.2x | -62.9x | 3.2x |
| Sun, 26 Mar 2023 | HK$338.0b | HK$91.1b | -HK$1,678,004,876.00 | 533.8x | -201.5x | 3.7x |
Price to Earnings Ratio
-201.5x
Current Industry PE
- Investors are pessimistic on the Hong Kong Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 59.1x which is lower than its 3-year average PE of 146x.
- The 3-year average PS ratio of 2.3x is higher than the industry's current PS ratio of 1.3x.
Past Earnings Growth
- Total earnings for the Drug Retail industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 4.5% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Comparison
How does Hong Kong Drug Retail compare with similar industries?
| HK Market | 3.58% | |
| Consumer Staples | 5.02% | |
| Food and Staples Retail | 4.71% | |
| Drug Retail | 6.49% | |
| Big Box Super Stores | 6.26% | |
| Food Retail | 1.37% | |
| Food Distributors | -3.44% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6618 JD Health International | HK$24.80 | 6.7% +HK$4.9b | -55.9% | PE34.2x | |
| 241 Alibaba Health Information Technology | HK$2.75 | 3.8% +HK$1.6b | -51.1% | PE50.1x | |
| 1833 Ping An Healthcare and Technology | HK$10.48 | 4.0% +HK$447.5m | -46.3% | PS2.3x | |
| 9886 Dingdang Health Technology Group | HK$1.09 | 4.8% +HK$67.1m | -63.3% | PS0.3x |
